上皮样肉瘤及其预后：来自印度北部一家三级护理中心的回顾性分析。
Epithelioid sarcoma and its outcome: a retrospective analysis from a tertiary care center in North India.
作者信息
Kashyap Divya, Rastogi Sameer, Garg Vikas, Shrivastava Shakti, Barwad Adarsh, Shamim Shamim A, Hemrom Angel, Dhamija Ekta, Bhoriwal Sandeep, Garg Rakesh
机构信息
Department of Medical Oncology, AIIMS, New Delhi, 110029, India.
Department of Pathology, AIIMS, New Delhi, 110029, India.
出版信息
Future Sci OA. 2023 Jan 10;8(9):FSO822. doi: 10.2144/fsoa-2021-0138. eCollection 2022 Oct.
AIM
Clinicopatholgical findings and outcomes in epithelioid sarcoma (ES) patients.
MATERIALS & METHODS: ES patients registered in sarcoma clinic from 2015 to 2021.
RESULTS
There were 20 patients with median age of 26 years. Majority had distal ES (70%) and advanced disease (85%). In patients with advanced disease lymph nodes were involved in 65%, lungs in 58% and others in 35%. Among 14 patients who underwent biopsy outside our institute, nine (64.2 %) had been initially misdiagnosed. Response rates to doxorubicin (n = 12), pazopanib (n = 6), gemcitabine/docetaxel (n = 5), tazemetostat (n = 3) and immunotherapy (n = 2) used in various lines were 16, 16, 20, 33 and 0%, respectively.
CONCLUSION
Our patients had an advanced-stage and distal ES, with a modest response to chemotherapy.
目的
上皮样肉瘤（ES）患者的临床病理特征及预后。
材料与方法
2015年至2021年在肉瘤诊所登记的ES患者。
结果
共20例患者，中位年龄26岁。大多数患者为远端ES（70%）且疾病处于晚期（85%）。晚期患者中，65%有淋巴结受累，58%有肺部受累，35%有其他部位受累。在14例在我院外接受活检的患者中，9例（64.2%）最初被误诊。不同治疗线使用的阿霉素（n = 12）、帕唑帕尼（n = 6）、吉西他滨/多西他赛（n = 5）、他泽司他（n = 3）和免疫治疗（n = 2）的缓解率分别为16%、16%、20%、33%和0%。
结论
我们的患者患有晚期远端ES，对化疗反应一般。
Zotero 插件